Recursion Pharmaceuticals, Inc.’s RXRX share price has dipped by 11.85%, which has investors questioning if this is right ...

Financing will support advancement of preclinical immunology pipeline. SAN DIEGO, April 04, 2025--(BUSINESS WIRE)--RayThera, ...

Solriamfetol, a new treatment for ADHD, showed a 45% reduction in symptoms in a Phase 3 trial. This treatment targets ...

Vividion Therapeutics, Inc. has announced that the first patient has been dosed in a Phase I clinical trial evaluating ...

Recursion Pharmaceuticals—a relatively small company backed by the chip giant Nvidia—is betting that its massive ...

Isomorphic Labs says it is advancing drug design programs across multiple therapeutic areas and drug modalities. These ...

Artificial intelligence (AI) is making significant strides in various fields, with drug discovery being one of the most impactful areas. The process of developing new drugs has traditionally been a ...

VVD-159642, Vividion's fourth clinical-stage program stemming from its chemoproteomics discovery platform, is designed to improve patient outcomes by inhibiting RAS-PI3Ka, a key signaling pathway ...

Explore Q1 2025's biotech stock moves, from CervoMed's 300% surge to Septerna's struggles. Click for my review of the quarter ...

Discover March 2025’s top biotech deals, featuring major collaborations in small molecules, bispecific antibodies and protein ...

In addition to these seven FDA-approved compounds, fifty are in clinical trials including four in Phase 3. Fragment-based drug discovery is a multidisciplinary approach that starts with the design ...